International Myeloma Working Group recommendations for global myeloma care
Now more than ever before, multiple myeloma patients are assessed and treated more precisely. New technologies are now able to “evaluate the biology and extent of the disease,” including the following:
- cytogenetic information
- genetic abnormalities
- extramedullary manifestations
- minimal residual disease
New and more effective drugs are now being used in clinical practice and greatly improve the outcome of patients but may also lead to specific side effects. These side effects need management, and may also be preventable.
For this reason, “it is important to identify the minimal requirements for diagnosis and treatment of patients.” Many patients may not have access to the most sophisticated advances depending on where they are receiving treatment. These recommendations discuss:
- the minimal requirements and options for diagnosis
- the monitoring and treatment of patients with multiple myeloma
Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R, Lentzsch S, Ming Chen W, Hou J, Jurczyszyn A, Romeril K, Hajek R, Terpos E, Shimizu K, Joshua D, Hungria V, Rodriguez Morales A, Ben-Yehuda D, Sondergeld P, Zamagni E, Durie B.
Click here to view article: